Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Continued Panitumumab Treatment
NCT00425204Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2004
- Primary completion
- Sep 2007
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of panitumumab in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), prostate cancer (PCa), renal cell carcinoma (RCC), solid tumor, sponsored by Amgen. Started Mar 2004; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)prostate cancer (PCa)renal cell carcinoma (RCC)solid tumor
Beyond the preview
Go deeper on NCT00425204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00425204.